期刊
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
卷 229, 期 -, 页码 -出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2021.114053
关键词
Multiple myeloma; Small molecular agents; Research overview
资金
- National Natural Science Foundation of China [82073311]
- National Key Research and Development Program of China [2020YFC2005500]
- Key Research and Development Program of Science and Technology Department of Sichuan Province [2019YFS0514]
- Applied basic research program of Science and Technology Department of Sichuan Province [2019YJ0576]
Multiple myeloma is currently incurable, and scientists are working on developing drugs with higher specificity to improve treatment outcomes.
Multiple myeloma is currently incurable, and the incidence rate is increasing year by year worldwide. Although in recent years the combined treatment plan based on proteasome inhibitors and immuno-modulatory drugs has greatly improved the treatment effect of multiple myeloma, most patients still relapse and become resistant to current treatments. To solve this problem, scientists are committed to developing drugs with higher specificity, such as iberdomide, which is highly specific to ikaros and aiolos. This review aims to focus on the small molecular agents that are being researched/clinically used for the treatment of multiple myeloma, including the target mechanism, structure-activity relationship and application prospects of small molecular agents. (c) 2021 Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据